GlassScriptPhysician profile
Raymond L Raitz
NPI 1558368423
$5,966.08
in general payments reported to CMS, 2019-2025
42 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $744 · 2021: $1,480 · 2022: $1,104 · 2023: $942 · 2024: $645 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.03 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $733.56 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $383.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $383.36 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $378.44 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $352.03 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $340.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $316.54 | 2019-2023 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $252.85 | 2019-2025 | Rybelsus, Ozempic |
| Genzyme Corporation | $184.84 | 2022-2025 | |
| Amarin Pharma, INC. | $183.19 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $144.33 | 2019-2021 | |
| Allergan, INC. | $132.55 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $116.44 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $107.66 | 2019-2025 | Capvaxive |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Raitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.